| Year |
Citation |
Score |
| 2023 |
Song HW, Benzaoui M, Dwivedi A, Underwood S, Shao L, Achar S, Posarac V, Remley VA, Prochazkova M, Cai Y, Jin P, Somerville RP, Stroncek DF, Altan-Bonnet G, Shah NN, ... ... Highfill SL, et al. Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output. Molecular Therapy. Methods & Clinical Development. 32: 101171. PMID 38298420 DOI: 10.1016/j.omtm.2023.101171 |
0.44 |
|
| 2023 |
Mikkilineni L, Natrakul DA, Lam N, Manasanch EE, Mann J, Weissler KA, Wong N, Brudno JN, Goff SL, Yang JC, Ganaden M, Patel R, Zheng Z, Gartner JJ, Martin KR, ... ... Highfill SL, et al. Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 38155568 DOI: 10.1016/j.ymthe.2023.12.018 |
0.407 |
|
| 2023 |
Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, Reynolds W, Gutierrez NA, Baskar R, Wu CJ, Michor F, Altreuter J, Liu Y, Jhaveri A, Duong V, ... ... Highfill SL, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. PMID 38134936 DOI: 10.1016/j.ccell.2023.11.011 |
0.431 |
|
| 2023 |
Cai Y, Prochazkova M, Kim YS, Jiang C, Ma J, Moses L, Martin K, Pham V, Zhang N, Highfill SL, Somerville RP, Stroncek DF, Jin P. Assessment and comparison of viability assays for cellular products. Cytotherapy. PMID 38085197 DOI: 10.1016/j.jcyt.2023.11.008 |
0.348 |
|
| 2023 |
Brudno JN, Natrakul DA, Karrs JX, Patel N, Maass-Moreno R, Ahlman MA, Mikkilineni L, Mann J, Stroncek DF, Highfill SL, Fromm GC, Patel R, Pittaluga S, Kochenderfer JN. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase I trial. Blood Advances. PMID 37939262 DOI: 10.1182/bloodadvances.2023011470 |
0.347 |
|
| 2023 |
Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou HC, Song YK, et al. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell Reports. Medicine. 101212. PMID 37774704 DOI: 10.1016/j.xcrm.2023.101212 |
0.401 |
|
| 2023 |
Ma J, Shao L, Fuksenko T, Liu H, Shi R, Dinh A, Highfill SL, Zhang N, Panch SR, Somerville RP, Stroncek DF, Jin P. Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays. Cytotherapy. PMID 36935289 DOI: 10.1016/j.jcyt.2023.02.010 |
0.316 |
|
| 2022 |
Dreyzin A, Panch SR, Shalabi H, Yates B, Highfill SL, Jin P, Stroncek D, Shah NN. Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells. Molecular Therapy. Methods & Clinical Development. 28: 51-61. PMID 36620075 DOI: 10.1016/j.omtm.2022.12.004 |
0.522 |
|
| 2022 |
Shao L, Shi R, Zhao Y, Liu H, Lu A, Ma J, Cai Y, Fuksenko T, Pelayo A, Shah NN, Kochenderfer JN, Norberg SM, Hinrichs C, Highfill SL, Somerville RP, et al. Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products. Journal of Translational Medicine. 20: 514. PMID 36348415 DOI: 10.1186/s12967-022-03729-5 |
0.352 |
|
| 2022 |
Smith RH, Bloomer H, Fink D, Keyvanfar K, Nasimuzzaman M, Sancheznieto F, Dutta R, Guenther Bui K, Alvarado LJ, Bauer TR, Hickstein D, Russell D, Malik P, Van Der Loo J, Highfill SL, et al. Preclinical Evaluation of Foamy Virus Vector-Mediated Gene Addition in Human Hematopoietic Stem/Progenitor Cells for Correction of LAD-1. Human Gene Therapy. PMID 36094106 DOI: 10.1089/hum.2022.065 |
0.309 |
|
| 2022 |
Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, Ligon JA, Silbert S, DéDé K, Benzaoui M, Goldberg SY, Achar S, Schneider D, Shahani SA, Little L, ... ... Highfill SL, et al. CD19/22 CAR T-cells in Children and Young Adults with B-ALL: Phase I Results and Development of a Novel Bicistronic CAR. Blood. PMID 35605184 DOI: 10.1182/blood.2022015795 |
0.38 |
|
| 2022 |
Holland EM, Molina JC, Dede K, Moyer D, Zhou T, Yuan CM, Wang HW, Stetler-Stevenson M, Mackall C, Fry TJ, Panch S, Highfill S, Stroncek D, Little L, Lee DW, et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. Journal For Immunotherapy of Cancer. 10. PMID 35534047 DOI: 10.1136/jitc-2021-004483 |
0.393 |
|
| 2022 |
Song HW, Somerville RP, Stroncek DF, Highfill SL. Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies. International Reviews of Immunology. 1-11. PMID 35486592 DOI: 10.1080/08830185.2022.2067154 |
0.479 |
|
| 2021 |
Cai Y, Prochazkova M, Jiang C, Song HW, Jin J, Moses L, Gkitsas N, Somerville RP, Highfill SL, Panch S, Stroncek DF, Jin P. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control. Journal of Translational Medicine. 19: 523. PMID 34952597 DOI: 10.1186/s12967-021-03193-7 |
0.346 |
|
| 2021 |
Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, Wang Y, Inglefield J, Dulau Florea A, Ceppi F, Hermida LC, Stringaris K, Dunham K, Homan PJ, Jailwala P, ... ... Highfill SL, et al. Characterization of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR T-Cells. Blood. PMID 34525183 DOI: 10.1182/blood.2021011898 |
0.486 |
|
| 2021 |
Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nature Medicine. PMID 33888899 DOI: 10.1038/s41591-021-01326-5 |
0.416 |
|
| 2021 |
Purwar R, Dwivedi A, Karulkar A, Ghosh S, Srinivasan S, Kumbhar BV, Jaiswal AK, Kizhakeyil A, Asija S, Rafiq A, Kumar S, Nisar A, Patil DP, Poojary MV, Jain H, ... ... Highfill SL, et al. Robust anti-tumor activity and low cytokine production by novel humanized anti-CD19 CAR-T cells. Molecular Cancer Therapeutics. PMID 33632869 DOI: 10.1158/1535-7163.MCT-20-0476 |
0.512 |
|
| 2021 |
Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, Stevanović S, Trimble CL, Kanakry JA, Bagheri MH, Ferraro E, ... ... Highfill S, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nature Medicine. PMID 33558725 DOI: 10.1038/s41591-020-01225-1 |
0.36 |
|
| 2020 |
Keskar V, Sood A, Loghin E, Kovacs E, Duthie RS, Liu S, Park JH, Chadwick C, Smith R, Brown M, Stroncek DF, Highfill SL. Novel DNA-based T-Cell Activator Promotes Rapid T-Cell Activation and Expansion. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 32796275 DOI: 10.1097/Cji.0000000000000329 |
0.519 |
|
| 2020 |
Lu A, Liu H, Shi R, Cai Y, Ma J, Shao L, Rong V, Gkitsas N, Lei H, Highfill SL, Panch S, Stroncek DF, Jin P. Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products. Journal of Translational Medicine. 18: 191. PMID 32384903 DOI: 10.1186/S12967-020-02358-0 |
0.502 |
|
| 2020 |
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, et al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903279. PMID 32286905 DOI: 10.1200/Jco.19.03279 |
0.529 |
|
| 2020 |
Nelson RC, Fellowes V, Jin P, Liu H, Highfill SL, Ren J, Szymanski J, Flegel WA, Stroncek DF. Group O plasma as a media supplement for CAR-T cells and other adoptive T-cell therapies. Transfusion. PMID 32167176 DOI: 10.1111/Trf.15745 |
0.495 |
|
| 2020 |
Norberg S, Nagarsheth N, Sinkoe A, Adhikary S, Meyer T, Lack J, Kanakry JA, Bagheri M, Schweitzer C, Astrow SH, Bot A, Stroncek D, Gkitsas N, Highfill S, Hinrichs CS. Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers. Journal of Clinical Oncology. 38: 101-101. DOI: 10.1200/Jco.2020.38.15_Suppl.101 |
0.487 |
|
| 2020 |
Clara JA, Reger R, Chakraborty M, Highfill SL, Jin J, Stroncek DF, Childs RW. Cell Density of NK Cells during Ex Vivo Expansion Impacts NK Cell Surface TRAIL Expression Blood. 136: 5-6. DOI: 10.1182/blood-2020-141487 |
0.353 |
|
| 2020 |
Mikkilineni L, Manasanch EE, Vanasse D, Brudno JN, Mann J, Sherry R, Goff SL, Yang JC, Lam N, Maric I, Stetler-Stevenson M, Wang H, Yuan CM, Stroncek DF, Highfill SL, et al. Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Blood. 136: 50-51. DOI: 10.1182/BLOOD-2020-138839 |
0.36 |
|
| 2020 |
Shalabi H, Yates B, Shahani S, Qin H, HIghfill SL, Panch S, Tran M, Stroncek D, Hoffman L, Little L, Graap K, Stetler-Stevenson M, Yuan C, Wang H, Fry TJ, et al. Abstract CT051: Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct051 |
0.422 |
|
| 2020 |
Lichtenstein DA, Steinberg SM, Highfill SL, Yates B, Jin P, Jin J, Panch S, Shalabi H, Stroncek DF, Fry TJ, Shah NN. Abstract 4231: Factors predictive of CAR T cell associated hemophagocytic lymphohistiocytosis (HLH) Cancer Research. 80: 4231-4231. DOI: 10.1158/1538-7445.Am2020-4231 |
0.573 |
|
| 2020 |
Fellowes V, Cai Y, Rodriguez-Mesa E, Grandinetti P, Jin J, Highfill SL, Schneider D, Dropulic B, Stroncek D, Gress R, Gattinoni L. Development of a closed system process for purifying naive CD8+ cells, culturing and transducing with a CD19/22 chimeric antigen receptor (CAR) to produce a clinical T memory stem cell product directed against B cell malignancies Cytotherapy. 22. DOI: 10.1016/J.Jcyt.2020.03.288 |
0.513 |
|
| 2019 |
Panch SR, Reddy OL, Li K, Bikkani T, Rao A, Yarlagadda S, Highfill S, Fowler D, Childs RW, Battiwalla M, Barrett J, Larochelle A, Mackall C, Shah N, Stroncek DF. Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument. Clinical Hematology International. 1: 161-167. PMID 34595426 DOI: 10.2991/chi.d.190529.001 |
0.358 |
|
| 2019 |
Stroncek DF, Reddy O, Highfill S, Panch SR. Advances in T-cell Immunotherapies. Hematology/Oncology Clinics of North America. 33: 825-837. PMID 31466607 DOI: 10.1016/J.Hoc.2019.05.006 |
0.536 |
|
| 2019 |
Highfill SL, Stroncek DF. Overcoming Challenges in Process Development of Cellular Therapies. Current Hematologic Malignancy Reports. PMID 31278568 DOI: 10.1007/S11899-019-00529-5 |
0.383 |
|
| 2019 |
Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, Highfill SL, Li X, Dagur P, Kochenderfer J, Fry TJ, Mackall CL, Lee D, Shah NN, Stroncek DF. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31178392 DOI: 10.1016/J.Ymthe.2019.05.015 |
0.511 |
|
| 2019 |
Ramakrishna S, Highfill SL, Walsh Z, Nguyen SM, Lei H, Shern JF, Qin H, Kraft IL, Stetler-Stevenson M, Yuan CM, Hwang JD, Feng Y, Zhu Z, Dimitrov D, Shah NN, et al. Modulation of Target Antigen Density Improves CAR T Cell Functionality and Persistence. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31110075 DOI: 10.1158/1078-0432.Ccr-18-3784 |
0.485 |
|
| 2019 |
Elavia N, Panch SR, McManus A, Bikkani T, Szymanski J, Highfill SL, Jin P, Brudno J, Kochenderfer J, Stroncek DF. Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics. Transfusion. PMID 30973976 DOI: 10.1111/Trf.15287 |
0.534 |
|
| 2019 |
Green DS, Nunes AT, Tosh KW, David-Ocampo V, Fellowes VS, Ren J, Jin J, Frodigh SE, Pham C, Procter J, Tran C, Ekwede I, Khuu H, Stroncek DF, Highfill SL, et al. Production of a cellular product consisting of monocytes stimulated with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for human use. Journal of Translational Medicine. 17: 82. PMID 30871636 DOI: 10.1186/S12967-019-1822-6 |
0.403 |
|
| 2019 |
Liu S, Stroncek DF, Zhao Y, Chen V, Shi R, Chen J, Ren J, Liu H, Bae HJ, Highfill SL, Jin P. Single cell sequencing reveals gene expression signatures associated with bone marrow stromal cell subpopulations and time in culture. Journal of Translational Medicine. 17: 23. PMID 30635013 DOI: 10.1186/S12967-018-1766-2 |
0.366 |
|
| 2019 |
Duemler A, Green DS, Highfill SL, Stroncek D, Zoon K, Annunziata CM. Production of autologous monocytes stimulated ex vivo with peg-interferon alfa 2b and interferon gamma 1b for intraperitoneal administration in phase I clinical trial. Journal of Clinical Oncology. 37: 5-5. DOI: 10.1200/Jco.2019.37.8_Suppl.5 |
0.396 |
|
| 2019 |
Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Shyu A, Highfill S, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, et al. Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy Blood. 134: 247-247. DOI: 10.1182/Blood-2019-131024 |
0.512 |
|
| 2019 |
Jin J, Reger R, Panch S, Childs R, Stroncek D, Highfill SL. Human natural killer cell manufacturing using a closed system process for patients with metastatic solid tumors or hematologic malignancies Cytotherapy. 21. DOI: 10.1016/J.Jcyt.2019.03.369 |
0.427 |
|
| 2018 |
Green DS, Nunes AT, David-Ocampo V, Ekwede IB, Houston ND, Highfill SL, Khuu H, Stroncek DF, Steinberg SM, Zoon KC, Annunziata CM. A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer. Journal of Translational Medicine. 16: 196. PMID 30012146 DOI: 10.1186/S12967-018-1569-5 |
0.328 |
|
| 2018 |
Jin P, Chen W, Ren J, Chen S, Wood L, Zhao Y, Remaley A, Pham C, Lian S, Liu S, Liu H, Highfill S, Berzofsky JA, Stroncek DF. Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells. Cytotherapy. PMID 29655599 DOI: 10.1016/J.Jcyt.2018.03.001 |
0.355 |
|
| 2018 |
Jin J, Gkitsas N, Fellowes VS, Ren J, Feldman SA, Hinrichs CS, Stroncek DF, Highfill SL. Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules. Journal of Translational Medicine. 16: 13. PMID 29368612 DOI: 10.1186/S12967-018-1384-Z |
0.514 |
|
| 2018 |
Nagarsheth N, Norberg S, Doran SL, Kanakry JA, Adhikary S, Schweitzer C, Astrow SH, Faquin WC, Gkitsas N, Highfill S, Stroncek D, Hinrichs C. Regression of epithelial cancers in humans following t-cell receptor gene therapy targeting human papillomavirus-16 E7. Journal of Clinical Oncology. 36: 3043-3043. DOI: 10.1200/Jco.2018.36.15_Suppl.3043 |
0.446 |
|
| 2018 |
Cortese I, Barrett AJ, Stroncek DF, Highfill S, Beck E, Andrada F, Ohayon J, Dwyer J, Schindler M, Aue G, Reich D, Nath A, Muranski P. A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-Cells Blood. 132: 4535-4535. DOI: 10.1182/Blood-2018-99-119832 |
0.419 |
|
| 2018 |
Muranski P, Davies SI, Ito S, Koklanaris E, Superata J, Yu Q, Highfill SL, Sabatino M, Stroncek DF, Battiwalla M, Barrett AJ. Very Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy for Prevention of Viral Infection after Allogeneic T Cell Depleted Stem Cell Transplantation Blood. 132: 812-812. DOI: 10.1182/Blood-2018-99-119314 |
0.513 |
|
| 2018 |
Norberg SM, Nagarsheth N, Doran S, Kanakry JA, Adhikary S, Schweitzer C, Astrow SH, Faquin W, Gkitsas N, Highfill S, Hinrichs CS. Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7 Blood. 132: 492-492. DOI: 10.1182/Blood-2018-99-117017 |
0.451 |
|
| 2018 |
Srivastava SK, Panch SR, Jin J, Shalabi H, Shah NN, Highfill SL, Stroncek DF. Abbreviated T-Cell Activation on the Automated Clinimacs Prodigy Device Enhances Bispecific CD19/22 Chimeric Antigen Receptor T-Cell Viability and Fold Expansion, Reducing Total Culture Duration Blood. 132: 4551-4551. DOI: 10.1182/Blood-2018-99-116846 |
0.548 |
|
| 2018 |
Nadal R, Cherkasova E, Barisic S, Granadier D, Aue G, Wells B, Hawks G, Hughes T, Shalabi R, Stroncek D, Highfill S, Scurti G, Chen L, Reger R, Nishimura M, et al. A phase I study of HERV-E TCR transduced autologous T Cells (HERV-E TCR T Cells) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy283.133 |
0.481 |
|
| 2017 |
Stroncek DF, Lee DW, Ren J, Sabatino M, Highfill S, Khuu H, Shah NN, Kaplan RN, Fry TJ, Mackall CL. Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. Journal of Translational Medicine. 15: 59. PMID 28298232 DOI: 10.1186/S12967-017-1160-5 |
0.507 |
|
| 2017 |
Shah NN, Highfill SL, Shalabi H, Yates B, Kane E, Fellowes V, Delbrook C, Ren J, Jin J, Stroncek D, Fry TJ. CD4/CD8 T-Cell Selection Enhances CD22 CAR-T Cell Transduction and in-Vivo CAR-T Expansion: Updated Results on Phase I Anti-CD22 CAR Dose Expansion Cohort Blood. 130: 809-809. DOI: 10.1182/Blood.V130.Suppl_1.809.809 |
0.543 |
|
| 2017 |
Elavia N, McManus A, Highfill SL, Ren J, Shah NN, Fry TJ, Brudno J, Kochenderfer JN, Stroncek D, Panch SR. The Post-Thaw Recovery of Cryopreserved Chimeric Antigen Receptor (CAR) T-Cells during Manufacture Is Better Than That of Cryopreserved Peripheral Blood CD3+ Cells Blood. 130: 4475-4475. DOI: 10.1182/Blood.V130.Suppl_1.4475.4475 |
0.51 |
|
| 2017 |
Ramakrishna S, Nguyen SM, Qin H, Highfill SL, Kraft I, Shern J, Walsh Z, Dimitrov D, Fry TJ. Modulation of CD22 Antigen Density Improves Efficacy of CD22 Chimeric Antigen Receptor (CAR) T Cells Against CD22lo B-Lineage Leukemia and Lymphoma Blood. 130: 3894-3894. DOI: 10.1182/Blood.V130.Suppl_1.3894.3894 |
0.451 |
|
| 2017 |
Battiwalla M, Zhang N, Li Z, Whitehill G, Wong S, Jain P, Ito S, Muranski P, Highfill SL, Stroncek D, Barrett J. Selective depletion of alloreactive donor t cells with adenosine—clinical scale up for allogeneic stem cell transplantation Cytotherapy. 19. DOI: 10.1016/J.Jcyt.2017.02.028 |
0.479 |
|
| 2017 |
Highfill SL, Jin J, Fellowes V, Ren J, Ramakrishna S, Fry T, Stroncek D. CD4 and CD8 T-cell positive selection increases the robustness of the CD22 CAR T-cell manufacturing process Cytotherapy. 19. DOI: 10.1016/J.Jcyt.2017.02.022 |
0.5 |
|
| 2017 |
Muranski P, Whitehill G, Davies SI, Yu Q, Sabatino M, Highfill S, Khuu H, Chang M, Chawla U, Anandi P, Spyridonidis A, Ito S, Stroncek DF, Battiwalla M, Barrett AJ. Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells is a Safe Strategy to Prevent Viral Reactivation in Recipients of Allogeneic T Cell Depleted Stem Cell Transplant Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.349 |
0.525 |
|
| 2016 |
Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S, El-Etriby R, Galli S, Tsokos M, Orentas RJ, Mackall CL. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunology Research. PMID 27549124 DOI: 10.1158/2326-6066.Cir-15-0230 |
0.562 |
|
| 2016 |
Muranski P, Whitehill G, Draper D, Koklanaris E, Superata J, Yu Q, Sabatino M, Highfill SL, Khuu H, Davies SI, Chang M, Chawla U, Spyridonidis A, Fahle G, Ito S, et al. Early Adoptive Transfer of Ex Vivo Generated Multi-Virus Specific T Cells Is a Safe Strategy to Prevent Viral Reactivation in Recipients of Allogeneic T Cell Depleted Stem Cell Transplant Blood. 128: 979-979. DOI: 10.1182/Blood.V128.22.979.979 |
0.524 |
|
| 2015 |
Giles AJ, Reid CM, Evans JD, Murgai M, Vicioso Y, Highfill SL, Kasai M, Vahdat L, Mackall CL, Lyden D, Wexler L, Kaplan RN. Activation of hematopoietic stem/progenitor cells promotes immunosuppression within the pre-metastatic niche. Cancer Research. PMID 26719537 DOI: 10.1158/0008-5472.Can-15-0204 |
0.424 |
|
| 2015 |
Giles AJ, Murgai M, Vicioso Y, Highfill S, Kasai M, Vahdat L, Wexler L, Mackall C, Lyden D, Kaplan R. Abstract 4725: Hematopoietic stem cell niche activation and progenitor mobilization mediate cancer-associated immunosuppression and metastasis Cancer Research. 75: 4725-4725. DOI: 10.1158/1538-7445.Am2015-4725 |
0.39 |
|
| 2014 |
May SL, Zhou Q, Lewellen M, Carter CM, Coffey D, Highfill SL, Bucher CM, Matise I, Morse HC, O'Sullivan MG, Schutten M, Johnson C, Bellgrau D, Blazar BR, Modiano JF. Nfatc2 and Tob1 have non-overlapping function in T cell negative regulation and tumorigenesis. Plos One. 9: e100629. PMID 24945807 DOI: 10.1371/Journal.Pone.0100629 |
0.637 |
|
| 2014 |
Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Science Translational Medicine. 6: 237ra67. PMID 24848257 DOI: 10.1126/Scitranslmed.3007974 |
0.339 |
|
| 2013 |
Duncan BB, Highfill SL, Qin H, Bouchkouj N, Larabee S, Zhao P, Woznica I, Liu Y, Li Y, Wu W, Lai JH, Jones B, Mackall CL, Bachovchin WW, Fry TJ. A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 400-11. PMID 23994886 DOI: 10.1097/Cji.0B013E3182A80213 |
0.388 |
|
| 2013 |
Lundström W, Highfill S, Walsh ST, Beq S, Morse E, Kockum I, Alfredsson L, Olsson T, Hillert J, Mackall CL. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proceedings of the National Academy of Sciences of the United States of America. 110: E1761-70. PMID 23610432 DOI: 10.1073/Pnas.1222303110 |
0.336 |
|
| 2013 |
Highfill SL, Long AH, Orentas RJ, Mackall CL. Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors Journal For Immunotherapy of Cancer. 1: 265. DOI: 10.1186/2051-1426-1-S1-P265 |
0.516 |
|
| 2013 |
Giles A, Vicioso Y, Kasai M, Highfill S, Mendoza A, Kaplan R. Bone marrow-derived progenitor cells develop into myeloid-derived suppressor cells at metastatic sites Journal For Immunotherapy of Cancer. 1: 188. DOI: 10.1186/2051-1426-1-S1-P188 |
0.447 |
|
| 2013 |
Giles A, Vicioso Y, Persenaire C, Kasai M, Highfill S, Mendoza A, Kaplan R. Abstract LB-284: Bone marrow-derived progenitor cells develop into myeloid-derived suppressor cells at metastatic sites. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-284 |
0.419 |
|
| 2013 |
Long AH, Highfill SL, Haso WM, Orentas RJ, Mackall CL. Abstract 3974: Evaluating the susceptibility of solid tumors to chimeric antigen receptor modified T cell therapies. Cancer Research. 73: 3974-3974. DOI: 10.1158/1538-7445.Am2013-3974 |
0.534 |
|
| 2010 |
Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood. 116: 5738-47. PMID 20807889 DOI: 10.1182/Blood-2010-06-287839 |
0.697 |
|
| 2010 |
Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 116: 2484-93. PMID 20570856 DOI: 10.1182/Blood-2010-03-275446 |
0.539 |
|
| 2010 |
Vogtenhuber C, Bucher C, Highfill SL, Koch LK, Goren E, Panoskaltsis-Mortari A, Taylor PA, Farrar MA, Blazar BR. Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses. Blood. 116: 466-74. PMID 20442366 DOI: 10.1182/Blood-2009-11-252825 |
0.709 |
|
| 2009 |
Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, Levine BL, Riddle M, June CH, Vallera DA, Weigel BJ, Blazar BR. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 114: 3793-802. PMID 19724059 DOI: 10.1182/Blood-2009-03-208181 |
0.583 |
|
| 2009 |
Highfill SL, Kelly RM, O'Shaughnessy MJ, Zhou Q, Xia L, Panoskaltsis-Mortari A, Taylor PA, Tolar J, Blazar BR. Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming. Blood. 114: 693-701. PMID 19458354 DOI: 10.1182/Blood-2009-03-213850 |
0.751 |
|
| 2008 |
Kelly RM, Highfill SL, Panoskaltsis-Mortari A, Taylor PA, Boyd RL, Holländer GA, Blazar BR. Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation. Blood. 111: 5734-44. PMID 18334670 DOI: 10.1182/Blood-2008-01-136531 |
0.672 |
|
| 2008 |
Kelly RM, Highfill SL, Panoskaltsis-Mortari A, Taylor PA, Boyd RL, Hollaender GA, Blazar BR. KGF and androgen blockade work in concert to protect against conditioning regimen‐induced thymic epithelial damage and enhance T‐cell reconstitution following murine BMT The Faseb Journal. 22: 536-536. DOI: 10.1096/Fasebj.22.2_Supplement.536 |
0.387 |
|
| 2004 |
Ghansah T, Paraiso KH, Highfill S, Desponts C, May S, McIntosh JK, Wang JW, Ninos J, Brayer J, Cheng F, Sotomayor E, Kerr WG. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. Journal of Immunology (Baltimore, Md. : 1950). 173: 7324-30. PMID 15585856 DOI: 10.4049/Jimmunol.173.12.7324 |
0.548 |
|
| 2004 |
Wang JW, Gamsby JJ, Highfill SL, Mora LB, Bloom GC, Yeatman TJ, Pan TC, Ramne AL, Chodosh LA, Cress WD, Chen J, Kerr WG. Deregulated expression of LRBA facilitates cancer cell growth. Oncogene. 23: 4089-97. PMID 15064745 DOI: 10.1038/Sj.Onc.1207567 |
0.349 |
|
| Show low-probability matches. |